SOFTEC COVID-19 Antigen Rapid Test (Nasal) The COVID-19 Antigen Rapid Test Cassette (Nasal Swab) is a lateral flow immunoassay designed for the qualitative detection of SARS-CoV 2 nucleocapsid antigens in nasal swabs from individuals with suspected COVID-19 by health care providers. Results are for SARS-CoV-2 nucleocapsid antigen identification. The COVID 19 Antigen Rapid Test Cassette (Nasal Swab) is intended for use by medical professionals or trained operators experienced in performing lateral flow tests. The price of the product is determined by the number of orders.
.SOFTEC COVID-19 Antigen Test Kit (For Celt Test Use) Fast Easy to Use Reliable The SARS-CoV-2 Antigen Rapid Test (Nasal Swab) is a single-use test kit designed to detect SARS-CoV-2, the cause of COVID-19, with a self-collected nasal swab sample. The test is intended for use in symptomatic individuals who meet the definition of COVID-19 disease and is limited to asymptomatic individuals who have been in contact with confirmed or suspected cases of COVID-19 and at-risk healthcare workers. The SARS-CoV-2 Antigen Rapid Test (Nasal Swab) is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 nucleocapsid protein antigens in a human swab sample. There are single packs and 25 pieces of products. SOFTEC COVID-19 Antigen Test Kit (For Self-Test Use) (Pack of 25) The price of the product is determined by the number of orders.
SOFTEC COVID-19 IGG/IGM Antibody Test Kit (Single Pack) The COVID-19 IgG/IgM Rapid Test Cassette is a lateral flow chromatograpic immunoassay for the qualitative defection of antibodies (IgG and IgM) to Novel coronavirus in human Whole Blood/Serum/Plasma. It provides an aid in the diagnosis of intection with Novel coronavirus.
The COVID-19Antigen Rapid Test Cassette (Saliva) is a lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigens in saliva from individuals who are suspecte of COVID-19 by their healthcare provider. There are single pack and 25pcs products (SOFTEC COVID-19 Antigen Rapid Test (Saliva)25pcs Pack). The price of the product is determined by the number of orders.
The COVID-19 Antigen Rapid Test Cassette is a lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab and oropharyngeal swab from individuals who are suspected of COVID-19 by their healthcare provider. Results are for the identification of SARS-CoV-2 nucleocapsid antigen
[ZENITH GROUP] COVID-19 Test Kit o Product Name - Gendbody COVID-19 AG Test Kit - Gendbody COVID-19 AG Home Test Kit - Gendbody COVID-19 lgG/lgM o Price (USD) : 2.5$ (FOB) - Can be discussed up to order Qty - CIF : Can be discussed o Certification : CE,FDA o MOQ : 1,000 pcs o Payment : L/C, TT o Delivery Time - Up to Qty - Capacity : 3,000,000pcs / 1week Genbody Covid-19 AG Home Test Kit is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein from SARS-COV-2 from individual's nasal specimen with or without COVID-19 symptoms.
DYMIND COVID-19 Antigen Test Kit (Saliva Test Kit) - For Self Testing SARS-CoV-2 Antigen Test Kit (colloidal gold method) MALAYSIA DRUG AUTHORITY (MDA), KKM APPROVED Accurate + Fast + Easy Sensitivity: (95% CI): 123/129 95.35% (90.15% -98.27%) Specificity: (95% CI): 160/16398.16% (93.84% -99.33%) Ct count
1pc/box; 5pc/box; 20pc/box;
CLIA Waived Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests. This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. The CLIA Waived COVID-19 IgG/IgM Rapid Test Device is an in vitro immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only. Indication: Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories. About Test Device EUA Authorized CE Mark Test does NOT give positive or negative result for COVID-19 virus. This is an antibody test, it only indicates past or recent infection. Read Results in 15 Minutes 9 Month Expiration from Date of Manufacture Contents 20 Test Devices 20 Disposable Pipettes 20 Alcohol Prep Pads Sterile Safety Lancets Buffer Package Insert
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. Lateral flow assay Detect SARS-CoV-2 nucleocapsid protein antigen Rapid results within 10-15 minutes Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation For use under the Emergency Use Authorization (EUA) only For in vitro diagnostic use only For prescription use only For use with direct anterior nasal and nasopharyngeal swab specimens Clinical Performance 93.75% PPAa and 99.32% NPAb when used with nasopharyngeal swab 87.18% PPAa and 100% NPAb when used with anterior nasal swab
Master Carton - Contains 625 Tests For International Sale Only - Call for Pricing The COVID-19 IgG/IgM Rapid Test Device is an in vitro Immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only. Indication: Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. About Test Device Gives Positive or Negative Result for COVID-19 IgM/IgG antibodies Read Results in 15 Minutes Contents of each box 25 Test Devices 25 Disposable Pipettes 25 Alcohol Prep Pads Sterile Safety Lancets Buffer Package Insert
Big range of self Covid tests.
COVID-19 AG detection of SARS-CoV-2 antigen
The n-FasT SARS-CoV-2 diagnostic kit, has the Lamp method, which is among the most reliable detection methods. The reaction that reveals the diagnosis result for Covid-19 in a fast, practical and safe way yields results with a colorimetric method based on colour change. n-FasT differs from all other kits with the opportunity to give results below the patient within 30 minutes in application and with 97 % success rate result interpretation.
Direct to the seller side Covid-19 Rapid Antibody, Antigen Test Kits Covid-19 Vaccine -> Currently actively working with many govt bodies experiencing Massive success. after my own dd & NCNDA, will link you up directly to the sell side. this is as close as you can get to the end seller for this sort of commodity. Contact me for more information. There are however, a very high demand and I experience high volumes of enquiries daily and i do not wish to waste anyone time. Looking for a sincere long term working relationship/partnership. so any circumventing, funny business will not be tolerated.
Intended use: AIVD COVID-19(SARS-CoV-2) IgG/IgM Rapid Test is a single use, rapid device for qualitative detection of total antibodies against 2019 novel coronavirus (SARS-CoV-2) in human serum, plasma or whole blood specimens. The kit is intended for screening of patients suspected for infection with SARS-CoV-2, and as an aid in the diagnosis of the coronavirus disease 2019 (COVID-19). Descriptionï¼? Novel coronavirus pneumonia (NCP) or SARS-COV-2, that was officially named by the WHO as â??Corona virus disease 2019â?? (COVID-19), is a respiratory infection caused by a new virus that was first identified in late 2019. IgM/IgG Rapid Kit can specifically detect IgM and IgG antibodies of COVID-19, covering the entire course of infection and recovery period of patients. This approach improves the overall diagnosis of COVID-19 in both acute and recovery phases of illness. This kit utilizes the principle of colloidal gold immunochromatography to qualitatively detect the new coronavirus (COVID-19) IgG / IgM antibodies in human serum and plasma. Lateral flow immunochromatographic assay provides an easy workflow, short turnaround time, and rapid diagnosis of COVID-19 suspected patients. This method does not require expensive medical instruments and consumables. Just take the specimen and add it to the sample well, and then add the required amount of a diluent. The IgG / IgM antibodies in the sample will interact with the colloidal gold-labeled COVID-19 recombinant antigen on the conjugate pad. Then the conjugate pad will release re-solubilized conjugate onto the nitrocellulose membrane. The nitrocellulose membrane (NC membrane) diffuses it forward. As the sample moves along the device binding reagents situated on the nitrocellulose membrane bind to the target at the test line. If the sample contains a COVID-19 IgG antibodies, they will bind to the colloidal gold-labeled novel coronavirus recombinant antigen, diffuse forward, and then react with the anti-human IgG antibodies immobilized on the NC membrane detection line (T2 line). Similarly, if the specimen contains IgM antibodies to COVID-19, the antibodies will react with antigen-coated particles, the conjugate migrate laterally forward, and cause a colored line (T1 line). The darker the color of colloidal gold on the test line, the higher the concentration antibodies to COVID-19 in the sample. Accuracy:ï¼?> 90% Specificity: 97% Basic Protocolï¼? 1. Remove the test specimen, required reagents from storage conditions, and equilibrate to room temperature. 2. Unpack the aluminum foil bag, place the test horizontally on the table and number it. 3. Add 10ul serum, plasma or whole blood sample to the sample well with a pipette or a dropper. Slowly add 2 drops of sample dilution (about 60uL) to the sample well. 4. Read the results within 10-15 minutes after adding the sample, and the results will be invalid after 30 minutes.
Description This kit utilizes fluorescence quantitative probe-based PCR and guarantees a high specificity to ensure accurate one-step identification of ORF1ab and N genes of 2019-nCoV. The kit offers a highly sensitive test with a limit of detection as low as 500 copies/ml. The results are available within 1.5 hour. Kit Contents (48 Tests /Kit) Dual Enzyme solution A 50 µl Dual Ncvo-O / N reaction solution A 1 ml Dual Ncvo-O / N positive control A 200 µl Dual Negative control A 200µl Applicable equipment ABI series, Bio-Rad, Roche series and other fluorescent real-time PCR instruments. Specimens requirements Specimen type: nasopharyngeal swab from suspected infection; virus cell culture fluid, etc. Basic Protocol 1. Sample preparation. Take the test sample and extract the RNA nucleic acid according to the instructions of the nucleic acid extraction kit. The nucleic acid extraction product should be stored at -20 C. 2. Reaction mixture preparation According to the total number of test samples, the number of PCR reaction tubes needed is. N = number of samples + 1 negative control + 1 positive control. The following protocol is recommended for a 20 µl reaction volume. If the volume of reaction changes, please adjust proportionally. Components Volume Dual Enzyme solution A 1 µl Dual Ncvo-O / N reaction solution A 19µl Final Volume: 20 µl 3. Sample adding. Add 5 µl each of the extracted RNA, positive and of negative control to corresponding reaction tubes. After assembling all the components, cover the tube caps and gently mix the contents of the tube, mix well, and centrifuge briefly. 4. Perform quantitative PCR Place the reaction tube inside a real-time PCR instrument. Set the channel and sample information, reaction system volume 25 µl. Select the following channels: FAM channel for nCOV-ORF1ab, VIC channel for nCOV-N. Perform quantitative PCR using recommended cycling parameters settings: Step Temperature Time Number of cycles Fluorescence Detector 1 50C 15 min 1 Off 2 95C 3 min 1 Off 3 95C 10sec 45 Off 60C 30 sec On Result analysis: 1) Set the baseline: Generally, it is set to 6-15cycle for ABI 7500, 7700 and other instruments, 3-15cycle for PE5700, and 6-12cycle for MJ Research Option2. Under special circumstances, the baseline can be adjusted accordantly. 2) Set the threshold: The threshold line just exceeds the highest point of the negative control amplification curve (random noise line).
AIVD Biotechs COVID-19 Ag test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein (NP) antigen from SARS-CoV-2 in direct nasal swabs from individuals suspected of COVID-19. Description This kit utilizes the principle of latex bead immunochromatography to qualitatively detect the new coronavirus (COVID-19) Np antigen in human nasal swabs. Lateral flow immunochromatographic assay provides an easy workflow, short turnaround time, and rapid diagnosis of COVID-19 suspected patients. The test contains latex bead conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the test lines (T). If SARS-CoV-2 antigen is present in the specimen, a visible band appears on the test lines (T) as antibody-antigen-antibody latex bead complex forms. The control line (C) is used for procedural control and should always appear if the test is performed correctly. This method does not require expensive medical instruments and consumables. Just take the specimen and add it to the sample well. If sample contains the antigen, it will interact with the latex bead-labeled COVID-19 anti-SARS-COV-2 NP antibodies on the conjugate pad. Required components 1. A foil pouch with a desiccant and a single-use test card, 1 piece 3. Sterile swab, 1 piece 3. Extraction buffer tube (1 ml), 1 tube. 4. Instructions for use, 1 piece. Specimen requirements: 1. Nasopharyngeal swab specimen. 2.Specimen should be tested as soon as possible upon collection. If the sample has to be stored, store the swab sample at room temperature for up to 1 hour or 2~8â?? for up to 4 hours prior to testing. Specimen preparation 1. Insert the extraction buffer tube into the tube rack, make sure that the sample tube is firmly upright and touches the bottom of the rack. 2. Insert the swab into an extraction buffer tube. 3. Gently stir the swab in the tube, and then left swab inside the tube for 1 minute or Mix on the vortex mixer for about 30 seconds, 4. The sample should be tested immediately after collection. If it cannot be tested in time, it should be stored in the virus transport matrix. The specimens can be stored at 2-8C for 4 hours Basic Protocol Step 1: If the sample is refrigerated, remove the sample to be tested and the required reagents from the storage conditions, equilibrate to room temperature (15~30C) Step 2: When preparing to test, open the aluminum foil bag, take out the test card, and lay it flat on a table. Step 3: Mark the sample number on the test card, Step 4: Using pipette add 50ul of the sample into a sample well on the device, Step 5: Read the result within 15 minutes, Please read the result after 15 minutes. After observing and recording the result, please discard the test card to avoid affecting the result judgment. Do not read test results after 30 minutes. It may give false results.
The NeoPlexTM COVID-19 Detection Kit Assay is a real-time RT-PCR in vitro diagnostic test intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from respiratory specimens* obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria. The NeoPlexTM COVID-19 Detection Kit is for use only under Emergency Use Authorization (EUA) in the US laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.�§263a, to perform high complexity tests. CE & FDA Approved and MHRA Registered for UK
STANDARD M nCoV Real-Time Detection kit is used for rapid identification and detection of novel coronavirus (2019-nCoV) nucleic acids in human nasopharyngeal swabs and throat swab samples. - One tube reaction for identification and detection of 2019-nCoV - One-step Real-Time RT-PCR - Provide all reagents required for PCR - Designed according to WHO interim guidance for laboratory testing for 2019 novel coronavirus (2019-nCoV) in humans" - nCoV primers/probes ORF1ab (RdRp) gene, E gene - Provide Internal controls - Test time : 90mins - Specimen : Nasopharyngeal swab, Oropharyngeal swab, Sputum - Applicable machine : CFX96. ABI7500 - CE, FDA EUA
